Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study
暂无分享,去创建一个
P. Golino | E. Pezzullo | V. Russo | A. Rago | G. Nigro | A. D'onofrio | V. Parisi | G. Scognamiglio | E. Attena | V. Caso | M. Malvezzi Caracciolo d'Aquino | Francesco Martone | M. Malvezzi Caracciolo D’Aquino | A. D’Onofrio | M. Malvezzi Caracciolo D'Aquino | Marco Malvezzi Caracciolo D'Aquino | E. Pezzullo
[1] P. Golino,et al. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation , 2020, Seminars in Thrombosis and Hemostasis.
[2] P. Golino,et al. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score–Matched Study , 2020, Cardiovascular Drugs and Therapy.
[3] Jeroen J. Bax,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.
[4] P. Golino,et al. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study , 2020, Journal of clinical medicine.
[5] P. Golino,et al. Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation , 2020, Journal of blood medicine.
[6] P. Golino,et al. Update on Direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures: from clinical trials to real-world evidence. , 2019, Journal of cardiovascular pharmacology.
[7] P. Golino,et al. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. , 2019, Clinical therapeutics.
[8] G. Galasso,et al. Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study. , 2019, Clinical therapeutics.
[9] P. Golino,et al. Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late , 2019, Journal of cardiovascular pharmacology.
[10] A. Cassese,et al. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study , 2019, American Journal of Cardiovascular Drugs.
[11] P. Golino,et al. Atrial Fibrillation and Malignancy: The Clinical Performance of Non–Vitamin K Oral Anticoagulants—A Systematic Review , 2018, Seminars in Thrombosis and Hemostasis.
[12] F. Fedele,et al. Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study , 2019, Journal of cardiovascular medicine.
[13] P. Kirchhof,et al. Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. , 2018, Journal of the American College of Cardiology.
[14] G. Lip,et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis. , 2018, International journal of cardiology.
[15] A. Camm,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.
[16] N. Brunetti,et al. Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis , 2018, Journal of Thrombosis and Thrombolysis.
[17] C. Bancone,et al. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience , 2018, Seminars in Thrombosis and Hemostasis.
[18] P. Golino,et al. Use of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review , 2017, Seminars in Thrombosis and Hemostasis.
[19] P. Golino,et al. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study , 2018, Journal of Thrombosis and Thrombolysis.
[20] S. Iliceto,et al. NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world. , 2017, International journal of cardiology.
[21] V. Russo,et al. The clinical performance of dabigatran in the Italian real-life experience. , 2017, Journal of Cardiovascular Medicine.
[22] P. Calabrò,et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence , 2017, Therapeutic advances in drug safety.
[23] G. Lip,et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial , 2016, The Lancet.
[24] P. Kirchhof,et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. , 2016, American heart journal.
[25] R. de Caterina,et al. Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48 , 2016, Clinical cardiology.
[26] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[27] P. Calabrò,et al. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. , 2015, European review for medical and pharmacological sciences.
[28] A. Rapacciuolo,et al. Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: A multi center registry. , 2015, International journal of cardiology.
[29] V. Essebag,et al. Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials , 2015, Medical devices.
[30] A. Camm,et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.
[31] Jun Zhu,et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.
[32] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[33] J. Hartikainen,et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. , 2013, Journal of the American College of Cardiology.
[34] G. Breithardt,et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.
[35] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[36] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[37] S. Yusuf,et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.
[38] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[39] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.